The KEYNOTE-024 trial provided compelling evidence that pembrolizumab outperformed platinum-based chemotherapy in terms of prolonged progression-free and overall survival and fewer adverse events in patients with untreated advanced NSCLC with a PD-L1 tumor proportion score (TPS) of ≥50% [2]. Here, CD274 is linked to non-small cell lung carcinoma.